Percutaneous therapies for peripheral artery disease continue to evolve with new techniques and devices. Although guidelines-recommended therapies have impacted cardiovascular morbidity and mortality, endovascular interventions have been shown to reduce limb pain, improve quality of life, and prolong walking distance for those with claudication and to reduce amputation rates among those with critical limb ischemia. Novel devices such as drug-eluting stents and drug-coated balloons have improved patency for moderate-length lesions, whereas others allow treatment of heavily calcified and tortuous segments. New adjunctive devices to cross lesions and reduce or modify associated plaque have also been developed, although level 1 data regarding their efficacy are sparse. There has also been a better mechanistic understanding of lower extremity endovascular treatment using tools such as intravascular ultrasound. This information has highlighted the need for better stent size selection for the femoropopliteal arterial segments and larger balloon diameters for the tibial arteries. Moreover, a wound perfusion approach with direct in-line flow, the so-called angiosome approach, and reconstruction of the pedal loop have been advocated for improved wound healing. Technical advances such as the tibiopedal access and reentry methods have allowed crossing of lesions that were considered no option for the endovascular approach in the past. Collectively, there has been increased awareness, interest, and commitment by various specialty societies and organizations to advance the treatment of peripheral artery disease and critical limb ischemia. This is also evident by the recent coalition of 7 professional societies and organizations that represented >150 000 allied health professionals and millions of patients with peripheral artery disease at the 2015 Centers for Medicaid and Medicare Services Medicare Evidence Development and Coverage Analysis Committee meeting. The percutaneous therapies for peripheral artery disease continue to evolve with longer follow-up with randomized data and larger prospective registries. In the future, it is hopeful that we will treat the lower extremity arteries according to segments, taking into account plaque morphology, luminal versus subintimal crossing, location, and stenotic versus occlusive disease. Until then, we must identify the most cost-effective, efficacious, and safe treatment for each patient. The goal of this article is to aid the practicing vascular specialist consider the optimal choices for the management of patients with vascular disease.
T he incidence and prevalence of peripheral artery disease (PAD) continues to rise with >200 million individuals living with this diagnosis worldwide. 1 It has been associated with significant morbidity and mortality, and it is considered a coronary artery disease risk equivalent. 2, 3 All current guidelines recommend aggressive lifestyle and risk factor modification for patients with PAD to reduce the risk of major cardiovascular events and premature mortality. 2, 3 However, aside from a supervised exercise program and cilostazol, few medical advances have been shown to improve claudication walking distance or to prevent amputation in patients with critical limb ischemia (CLI). 4 Endovascular therapy, however, has been shown to reduce limb pain, improve quality of life, and prolong walking distance for those with claudication and has been associated with reduced amputation rates among those with CLI. [5] [6] [7] [8] [9] Many advances in devices and techniques have emerged, but it is more important to note that the body of evidence and quality of data in support of current devices and approaches continue to grow. These advances have led to a surge in long-term (5-year) randomized trials, head-to-head comparative studies, cost-effectiveness analyses, and multicenter registries. The purpose of this article is not to review all treatment strategies for PAD, because we specifically do not address comprehensive medical therapy and surgical revascularization, both of which have significant roles to play. In this article we will provide an in-depth review of the current state of percutaneous endovascular therapies for PAD.
CLInICAL PReSenTATIOnS AnD enD POInTS
PAD, defined by the Rutherford class, may present as asymptomatic (or having atypical features) or as the common symptom, claudication (Rutherford I-III). Patients with the more advanced form, CLI, present with ischemic rest pain, tissue loss, or gangrene (Rutherford IV-VI). Endovascular therapy has been recommended for patients with lifestyle-limiting (or disabling) claudication and for individuals with CLI. 2, 3, 10 Because of the different presentations (claudication versus CLI), different end points have been included in clinical trials, making comparisons of technologies challenging. For claudication device trials, primary patency has been the gold-standard end point, largely defined by regulatory agencies to support the notion that the treatment is safe and effective in restoring arterial perfusion through the treated segment. More recently, the combination of patency and clinically driven target lesion revascularization has gained momentum as a more relevant end point for treating patients with claudication. 11, 12 Other important end points include secondary patency, assisted primary patency, and quality-of-life metrics such as the Walking Impairment Questionnaire, the Short-Form-36 Physical Functioning Score, 13 the Peripheral Artery Questionnaire, 14 and the PAD Quality of Life Questionnaire. 15 However, given that the majority of patients are treated with endovascular therapy to improve pain-free walking distances (time), objective evidence of improving these parameters is most important. 5, 16 Treadmill exercise testing may allow objective assessment of the functional efficacy of available endovascular treatments beyond patency and quality-of-life questionnaires. 5, 16 Because many centers do not routinely perform objective treadmill exercise testing, use of the standardized 6-minute walk test has recently been adopted in claudication trials. 17 The main goal of endovascular intervention for CLI, unlike claudication, is to relieve rest pain, heal ischemic ulcers, and prevent amputation. In these patients, end points including amputation-free survival and major adverse limb events (MALEs), which include above-ankle amputation of the index limb or major reintervention (defined as new surgical bypass graft, jump or interposition graft revision, thrombectomy or thrombolysis), have been suggested. 18, 19 However, these end points fail to capture other important outcomes such as recurrent hospitalization for infection, pain control, endovascular reintervention, and impaired quality of life ( Figure 1 ). 20, 21 Because of these limitations, it is our belief that a renewed focus on complete wound healing, rates of wound healing, and time to wound healing may be a step forward for this field beyond amputation-free survival, MALE, and MALE plus perioperative death within 30 days. 20, 22 To this end, time to wound healing was recently shown to predict MALE, major amputation, and mortality in patients undergoing endovascular therapy for CLI ( Figure 2 ). 23 Indeed, the incremental value of current interventions is relatively small, and few interventions for CLI to date have shown a reduction in amputation rates. Therefore, time to wound healing may serve as an important end point to conduct comparative effectiveness trials among various techniques and endovascular strategies for CLI. However, given the heterogeneity of wound size, depth, and locations, better baseline assessment tools are required for a more balanced comparisons. We would suggest primary end points that would encompass MALE in combination with objective assessments of wound healing and pain relief (based on relevancy for the patient), and periprocedural complications.
once inflow disease has been addressed. Tissue loss, however, is associated with multilevel disease with a significant proportion of patients having infragenicular tibial and intrinsic pedal artery disease. 24 The technical expertise required, the devices used, and the patency for each segment are different and depend on the degree of stenosis or occlusion, lesion length, calcification, and clinical presentation. The main challenges for endovascular therapies continue to involve the CFA, distal superficial femoral and popliteal, and tibial and plantar arteries.
The CFA has been considered to be suboptimal for stent-based therapies, and it has been considered best treated with surgical endarterectomy and patch angioplasty. However, delayed incisional wound healing and infection, along with risks of performing even this surgical procedure in patients with advanced coronary and cerebrovascular disease, pose concerns for this as the primary treatment for all patients. Profunda femoris artery disease is also generally treated surgically given the relative importance of this artery as a collateral source for the lower leg when the superficial femoral artery (SFA) is diseased or occluded.
The distal one-third of the SFA and popliteal arteries have demonstrated poorer endovascular patency rates.
In addition, stent fractures have posed challenges for these arterial segments over time because of repetitive mechanical stressors. 25, 26 However, this has been changing with recent data and the availability of atherectomy, new stent designs, and percutaneous transluminal angioplasty (PTA) catheters coated with antiproliferative drugs. 26, 27 Infrapopliteal and intrinsic pedal arteries remain a challenge mainly because of the lack of devices that can address this region, the length of occlusions, severe calcification, small arterial diameters, and technical challenges. 28, 29 Surgical revascularization for multilevel PAD and CLI has demonstrated acceptable limb salvage rates but carries significant periprocedural complications, wound infections, and graft failures over time. 30, 31 Given the heterogeneity of anatomic presentations, The Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC) guidelines provided TASC A through D classification based on lesion length and stenotic versus occlusive disease. 32, 33 Traditionally, TASC A and B were considered ideal candidates for endovascular therapy, and TASC C and D were reserved for open surgery. However, with advancing techniques and devices, most experts now consider endovascular STATe OF The ART therapy as the first-line revascularization method for many patients with PAD. 10, 32, 34 The National Institutes of Health-sponsored BEST CLI trial (Best Endovascular versus Best Surgical Therapy in Patients With CLI), which is currently enrolling patients with Rutherford class IV to VI symptoms, should provide much needed guidance regarding the most appropriate revascularization approach in these patients.
eXPeRIenCe AnD OUTCOMeS
Endovascular procedures are performed by a variety of operators from different specialties including vascular surgeons, interventional radiologists and cardiologists, vascular medicine specialists, and some cardiovascular surgeons. Despite consensus guidelines for diagnosis and treatment of PAD, each specialty has its own specific recommendations for the required volume of cases and acquired knowledge to treat vascular disease. [35] [36] [37] Although progress in other vascular areas such as carotid disease have been made, few evidenced-based disease-specific guidelines (claudication versus CLI) are available for lower extremity PAD. 38, 39 Collectively, endovascular procedures for PAD have evolved and require not only technical skills, but also a full knowledge of all treatment options such as surgical, hybrid (combined surgical and endovascular procedures), and endovascular procedures. In addition, treating PAD and CLI requires a solid knowledge of noninvasive vascular testing, differential diagnosis of leg pain and lower extremity ulcers, risk and complications associated with all treatment options, and a full set of endovascular skill sets including the ability to recognize and manage procedural complications. These are all required so that optimal, personalized treatment can be offered to each patient. 20 Unlike PAD, CLI is a more advanced condition and these patients are much sicker. Treating this condition requires a multidisciplinary team and advanced endovascular skills for adequate restoration of limb perfusion. With CLI, there has been some interest in identifying centers of excellence that offer comprehensive wound care, podiatric care, orthotics, and infectious disease and vascular expertise. 40 However, no formal requirements or strategy to identify such centers have been identified. In general, with few exceptions, all patients with CLI and salvageable limbs should receive an attempt at revascularization before amputation. If such expertise is not available, a referral to centers with such expertise should be considered. In the future, research about the most appropriate teams to address PAD and CLI should provide better guidance to all parties involved.
MeDICAL AnD ADJUnCTIVe TheRAPY
Endovascular therapy has not been shown to improve survival or reduce cardiovascular risk in the PAD patient. Therefore, medical therapy including tobacco cessation, supervised exercise program (if available; if not, instructions on regular unsupervised walking programs must be provided), and lifestyle modification must be offered to all patients with PAD. 2,3,10 Following endovascular therapy, patients routinely receive 1 to 6 months of dualantiplatelet therapy and aspirin monotherapy indefinitely. However, this practice remains variable across the United States. 41 Furthermore, patients with CLI require aggressive wound and multidisciplinary care.
eVIDenCe FOR ReVASCULARIZATIOn
Lower extremity revascularization for claudication has been reserved for lifestyle-and vocational-limiting claudication. 2,3 A number of studies have shown that supervised exercise programs in comparison with medical therapy or unsupervised exercise are associated with marked improvements in maximum walking time, distance, and pain-free walking. 42, 43 However, there remains controversy about the benefit of endovascular therapy in comparison with supervised exercise programs. The CLEVER trial (Claudication: Exercise Versus Endoluminal Revascularization) compared optimal medical therapy versus a supervised exercise program and endovascular intervention for patients with lifestyle-limiting claudication and aortoiliac disease. 5 The prespecific fourth randomization arm, which combined exercise plus endovascular therapy, was termi- nated before completion because only 8 patients were randomly assigned to this arm. CLEVER showed a statistically significant increase in maximum walking time with a supervised exercise program in comparison with endovascular therapy; however, endovascular intervention was associated with better quality of life and less perception of pain. Furthermore, those who underwent endovascular intervention walked farther, faster, and had fewer physical limitations. Since CLEV-ER, a number of other publications have shown that supervised exercise and endovascular therapy actually complement each other; endovascular therapy relieves pain and improves quality of life and supervised exercise program improves function. 7, 8 The recent Agency for Heathcare Research and Quality review found that endovascular intervention, when added to exercise, improves both maximum walking distance and initial claudication distance more than endovascular intervention or exercise alone. 44 
SPeCIFIC enDOVASCULAR TeChnIQUeS

Chronic Total Occlusions
Stenotic lesions are typically straightforward and crossed intraluminally. However, ≈25% to 30% of lower extremity arterial lesions represent chronic complete (total) occlusions (CTOs), and this prevalence is much higher (70%-80%) among those patients with diabetes mellitus and CLI. 24 These lesions are frequently crossed using the looped-wire technique, which is usually via a subintimal approach. The subintimal strategy actually defines a new plane for passage of guidewires and catheters. It is important that a successful subintimal approach implies that the distal end of the intervention returns to the true lumen to ensure adequate distal arterial perfusion. Novel devices and techniques have also been introduced to allow recanalization and treatment of these complex CTO lesions. 45 One of these techniques, the retrograde tibiopedal approach, has significantly increased successful crossing of CTOs, particularly among patients with CLI. 18 These retrograde tibiopedal procedures may be performed with the assistance of transcutaneous duplex ultrasound guidance, limiting the exposure of the patient to excess radiation and iodinated contrast. 46 A number of CTO devices have also been developed ranging from manual differential dissection to motorized vibrational and motorized or manual rotational (spinning) crossing catheters (Table 1) . [47] [48] [49] [50] [51] The main technical limitation with CTO devices, in addition to cost, is the inability to steer or direct them, and the relatively steep learning curve associated with their use. Furthermore, few head-to-head data are available that can guide the best device for each specific lesion; hence, they are used based on operator experience rather than on an evidence-based approach.
ReenTRY TeChnIQUeS
Crossing a CTO results in subintimal entry, and there is a requirement for reentry into the distal true lumen. A number of devices have been developed for this approach. In addition to these devices, a number of procedural techniques have been described, including the controlled antegrade and retrograde subintimal tracking (CART), reverse CART, and parallel balloon technique (Figure 3 ). 52 In principal, these techniques use a moderate-sized balloon in the subintimal space to create a dissection plane and allow reentry into the lumen either via an antegrade or retrograde approach. 52 The most important aspect of these techniques is using an appropriately sized balloon catheter (ie, for SFA 4-5 mm) and multiple inflations if necessary. Occasionally, multiple attempts via the CART or reverse CART may be necessary to finally allow luminal crossing, typically with a hydrophilic guidewire ( Figure 3 ).
DeVICeS Percutaneous Transluminal (Balloon) Angioplasty Catheters
A number of devices are used to treat PAD; the most basic and commonly used device is an uncoated balloon. PTA has been performed for decades and represents the first nonsurgical breakthrough strategy; however, many advances have been made since the introduction of this technology. Cutting, scoring, or specialty balloons are now available, but data regarding their superior efficacy or safety over standard PTA are not currently available. These devices have been used for vessel preparation or standalone treatment but are more costly than PTA catheters. They are currently used sparingly for vessel preparation or for tibial angioplasty where other endovascular options are limited. 53, 54 Drug-coated balloons (DCBs) have become available in the past 2 years in the United States. 12, 55 These DCB catheters have 3 general components: the balloon, the antiproliferative drug, and the carrier (excipient) that promotes drug transfer to the artery wall. Two devices are commercially available in the United States and are indicated for treatment of femoropopliteal artery disease. Two-year patency data in comparison with PTA have been published. 11, 55 These devices vary significantly despite the fact that paclitaxel is the antiproliferative agent on each balloon. 27 Although no head-to-head comparisons between the devices are available, the 2-year patency for the IN.PACT balloon (Medtronic Vascular) was 78.9% in comparison with 58.6% for the Lutonix DCB (Lutonix/CR Bard). 27 There are limited data for safety and efficacy of DCBs versus self-expanding stents or drug-eluting stents (DES). However, a single-center randomized trial did compare DCB with DES and found that DES had lower restenosis rates at 6 months. 56 STATe OF The ART significant momentum in treating the femoropopliteal artery segments. Similar to self-expanding stents, these devices are now applied to much longer lesions in an offlabel manner and have had acceptable patency in large postmarket multicenter registries. 57 In the preapproval pivotal trials, both required predilatation with uncoated PTA catheters followed by DCB if no significant recoil or major flow-limiting dissections were present. For this reason, and given the cost, most operators perform PTA first followed by DCB, if PTA results are unacceptable. Others, however, use self-expanding stents after DCB, if needed, under the premise that DCB will address intimal proliferation and stents correct acute arterial recoil and flow-limiting dissections. Overall, however, a significant percentage of operators prefer limiting permanent metal stent implantation as an initial endovascular strategy. 26 
Stents
Balloon-expandable cobalt chromium or stainless steel and self-expanding nickel-titanium (Nitinol) stents have been used to treat lower extremity PAD. Balloon-expandable stents are typically used predominantly for the common iliac artery. These stents have a higher radial strength and allow for more precise placement.
Self-expanding stents have generally been used in the external iliac artery and SFA. A number of studies have evaluated the efficacy of self-expanding stents over PTA in the femoropopliteal artery. For short focal lesions, no significant differences were found 58 ; however, for longer lesions (mean lesion length, 6-8 cm), self-expanding stents have persistently shown superior 1-and 2-year patency. 4 Although the randomized clinical trials support the use of self-expanding stents over PTA in such lesion lengths, many patients in clinical practice present with lesions that are much longer, typically as long as 30 to 40 cm. Many operators are reluctant to place self-expanding stents in such long lesions given the paucity of data, cost, and the increased risk of restenosis. Restenosis in such lesions is difficult to treat and may be associated with progression of symptoms from claudication to ischemic rest pain. For this reason, alternative therapies or a mixed approach with DCB and spot stenting with shorter stents has been advocated. 26 DESs are currently available for the femoropopliteal and below knee proximal tibial arteries. Although early SIROCCO trials (Sirolimus-Coated Cordis Self-expandable Stent) (Cordis, a Johnson and Johnson Company) were negative, 59, 60 Zilver PTX (Cook Incorporated) has shown significant promise and has been evaluated in a large randomized clinical trial with >5-year followup. 61 This stent has shown better patency than PTA or PTA plus provisional bare self-expanding stents. Furthermore, registry data have shown acceptable patency with Zilver PTX DES in longer lesions ( Table 2) . 62 The main limitation of this technology has been the availability of only shorter stent lengths (in the United States), cost, and technical challenges with device deployment. More recently, longer stents and much easier deployment mechanisms have become available in the United States.
Endovascular stent grafts, which consist of a selfexpanding nitinol stent coated on its luminal surface with heparin-bonded expanded polytetrafluoroethylene, have been approved for use in the iliac and SFA in the United States. 63 These devices have been evaluated in a number of randomized trials, namely, the VIPER (Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease) and VIASTAR trials. 64, 65 In VIASTAR, at 3 years there was no significant difference between covered Viabahn and self-expanding stents. In the single-arm VIPER trial, the primary patency was 73%; however, the low patency rate has been ascribed to device oversizing. 64 One randomized trial did evaluate the Viabahn endoprosthesis versus PTA for long (17.3±7.8 cm) in-stent restenosis, and at 12 months, the stent graft had 74.8% primary patency in comparison with 28% for PTA. 66 Stent grafts are the only device in the lower extremities that have been tested in such long lesions; therefore, the less than ideal patency may be a reflection of lesion complexity. Furthermore, despite many technical advances including contour edge and heparin coating, the risk of stent thrombosis converting patients to an acutely ischemic limb continues to be a concern. In the past few years, the interwoven Nitinol wire stent (Abbott Vascular) has gained traction, in particular, for complex distal superficial femoral and popliteal artery lesions. This bare metal stent design has been shown to be fracture resistant and conformable to the vessel. The SUPERB IDE trial showed a 78.9% patency rate at 12 months in mean lesion lengths of 78.1 mm. 67 Since then, a number of publications in longer and more heavily calcified lesions have demonstrated acceptable patency rates with an absence of stent fractures. 68, 69 This stent has recently allowed more aggressive treatment of the popliteal artery and those arteries with significant calcification despite limited data. However, this stent also has many limitations; precise deployment is challenging, and vessel preparation and correct sizing is critical to allow for full device expansion and better patency.
Most recently, the 2-year results of a first-in-human trial of a bioresorbable drug-coated scaffold with a different antiproliferative agent, everolimus, was published and suggested that, in particularly short lesions (mean 35.7±16 mm) in the SFA or external iliac artery, the 2-year restenosis rate among 35 patients was 16.1%. 70 Future advances in this technology may address shortterm concerns about recoil and dissection and resolve concerns over long-term in-stent restenosis and fracture.
Atherectomy
Atherectomy has been developed to remove atherosclerotic plaque to restore arterial patency. Currently, 5 devices are available in the United States, each offering different mechanisms. These devices are designed to debulk plaque and, in some cases, modify plaque morphology, allow full expansion of endovascular technologies, and theoretically minimize dissections. This is even more relevant among lesions with moderate to severe calcification, because 74% of plaques associated with arterial dissection following PTA have significant arterial calcification. 71 The mechanism of action of laser includes the breaking of molecular bonds and generating thermal and kinetic energy. The byproducts of this ablative process are water, gas, and small particles. This technology has been evaluated in LACI I and II and more recently in the EXCITE trial (Excimer Laser Randomized Controlled Study for Treatment of Femoropopliteal). 72, 73 Both LACI studies were performed in patients with CLI and showed acceptable amputation-free survival. The EXCITE trial examined the efficacy of laser atherectomy plus PTA versus PTA alone for in-stent restenosis or occlusion in 250 patients. Laser atherectomy showed a significant reduction in target lesion revascularization at 6 months. 74 Unfortunately, there are no published data comparing laser atherectomy with DCB, DES, or covered stents.
Directional atherectomy has also been evaluated in single-arm multicenter registries, the largest of which was the DEFINITIVE LE trial (Determination of Effectiveness of the SilverHawk PerIpheral Plaque Excision System [SIlverHawk Device] for the Treatment of Infrainguinal Vessels/Lower Extremities). 75 In >800 patients, the effectiveness of the SilverHawk/TurboHawk atherectomy catheter was tested in the femoropopliteal and tibioperoneal arteries. A significant portion of the patients did receive PTA after atherectomy. Overall, 3.8% of patients experienced distal embolization, 5.3% experienced perforation, and 2.3% had dissections. In patients with claudication alone, there was a 78% patency with mean lesion lengths of 7.5 cm. Similarly, among those with critical limb ischemia, there was a 71% patency for lesion length of 7.2 cm with an associated limb salvage rate of 95%. The study was a single-arm trial, and no comparative data are available. Furthermore, the impact of this technology plus DCB or DES is unknown. Recent small studies have shown some promise, but many issues remain unsolved, including how much debulking is necessary and what the long-term outcomes of such an approach will be. 76 Rotational atherectomy using the Jetstream (Boston Scientific) or the peripheral Rotoblator have also been used. Jetstream has been evaluated in a small singlearm study with 172 patients. 77, 78 Overall device success was 99%, and freedom from target lesion revascularization at 12 months was 74%. This device has the advantage of ongoing aspiration and has also been approved for thrombus retrieval (Table 3) .
Orbital atherectomy (CSI) has been in clinical use for >1 decade and has been shown in small studies to reduce dissection rates and allow lower-pressure balloon inflations. 79 The device allows for continuous flow of blood and requires a vasodilatory solution. The orbital motion is designed to create a smooth surface and allow plaque modification. 80 It has also been evaluated in multiple single-arm (some uncontrolled) studies involving >4000 patients including OASIS, CONFIRM I, II, III trials (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation), and COMPLI-ANCE 360° (Table 3) . 79, [81] [82] [83] The Phoenix (Volcano) front-cutting atherectomy uses blades to shave material directly from the artery wall into the device, hopefully minimizing embolization. However, few data regarding the safety and efficacy of this technology are currently available.
Other Adjunctive Therapies
The major limitation of endovascular therapy for PAD is restenosis. Historically, a number of attempts have been made to minimize or delay neointimal proliferation, inflammation, and restenosis. In addition to DES and DCBs, a number of technologies have been tested, including external beam radiation, brachytherapy, intravascular sonography, and cryoplasty; however, none has gained significant clinical use nor do these adjuvant technologies offer significant advantages. [84] [85] [86] PROCeDURAL IMAGInG TO IMPROVe TeChnICAL OUTCOMeS: InTRAVASCULAR ULTRASOUnD, FRACTIOnAL FLOW ReSeRVe, OPTICAL COheRenCe TOMOGRAPhY There has been significant progress using adjunctive procedural imaging in treating coronary artery disease. Some of these modalities have also been used extensively in other vascular territories, including the renal arteries, and for assessment of significance of iliac vein compression (May Thurner syndrome). However, intravascular ultrasound (IVUS) and fractional flow reserve (FFR) have gained little traction in the endovascular treatment of lower extremity PAD. Recent data using IVUS to treat iliac artery disease have shown significant clinical utility for vessel size assessment and stent apposition. 34, 87 Furthermore, proper stent selection for femo-ropopliteal PAD continues to be a challenge, and almost all devices continue to have suboptimal outcomes when oversized or undersized. This has been relevant for DES, DCB, SUPERA, and covered stents. [88] [89] [90] [91] [92] [93] IVUS-assessed minimum stent area has already been shown to predict in-stent restenosis in single-center studies. 94 Despite this, stent selection in the femoropopliteal lesion remains subjective and commonly results in over-or undersizing. Unfortunately, IVUS is not currently reimbursed for use in the lower extremity, and, unlike the coronary arteries, there is a paucity of data regarding its advantage and potential algorithms for its use. 34 FFR is used extensively in the coronary arteries, and, in randomized trials, it has been shown to guide appropriate therapy for coronary artery lesions of intermediate severity. 95 Its utility in PAD, however, is less defined. 96 Small single-center studies have shown some advantages. However, there remain many unanswered questions including: what is considered a significant FFR in the femoropopliteal versus tibial arteries; what is the optimal provocative hyperemic agent; at what dose is maximal vasodilatation achieved; what is the correlation between FFR findings and restenosis; and finally, the cost-effectiveness of FFR-guided therapy for lower extremity PAD is unknown. 96 The utility of FFR is important because of the paradigm shift in using fewer stents when faced with post-PTA dissection and recoil. 26 Should these dissections be treated or observed, and are subjective assessments good enough to determine the future patency of these segments after DCB? FFR may have an important role in this setting, but there is need for more data.
Optical coherence tomography has also been studied in the coronary anatomy; however, unlike IVUS, it has not received significant clinical adoption. Nevertheless, optical coherence tomography is currently used as an imaging tool for crossing lesions, and novel combination atherectomy devices with optical coherence tomography guidance are on the horizon. Last, unlike the coronary bed where almost all lesions are treated with DES, PAD is diffuse and involves long segments. Given the number of endovascular technologies that are available, can assessment of plaque morphology as defined by optical coherence tomography result in improved outcomes? Understanding plaque composition may guide selection of an appropriate atherectomy device, DCB versus DES, and may even allow a more cost-effective and personalized treatment algorithm based on plaque morphology rather than the anatomic location or length of the diseased arterial segment. 27 
ReCOMMenDeD enDOVASCULAR TReATMenTS BY AnATOMIC SeGMenT
The subsequent sections provide suggested endovascular strategies based on literature. However, there are scenari- STATe OF The ART os in which clinical practice has advanced faster than publication of peer-reviewed data. In those cases, we suggest alternate strategies; however, these are not based on litera-ture, and many devices are used off-label by practitioners who feel that these strategies are best for their patients. We are not endorsing any specific category or device. 
Aortoiliac
Endovascular therapy has been shown to be equivalent to surgical revascularization for aortoiliac disease regarding short-term patency but has significantly lower procedural morbidity and mortality. 97, 98 These data arose comparing PTA alone with surgery; however, stenting has been found to be superior to PTA for the aortoiliac segment with higher technical success rates, excellent durability, and fewer complications ( Figure 4A ). 99 Stents had a 39% higher primary patency than PTA, and the results were consistent regardless of whether the presenting symptoms were claudication or CLI. 100 However, these data most likely represent TASC A and B lesions. Currently, most operators and some guidelines recommend an endovascular first approach for the majority of TASC classifications including TASC C and D lesions. 32, 101 Stent selections for treating aortoiliac disease are usually operator dependent, but most op-erators recommend balloon-expandable stents for the common iliac artery and self-expanding stents for the external iliac arteries. 102 Balloon-expandable covered stents have also been evaluated for treating the common iliac artery with acceptable patency, but there have been conflicting results in comparison with bare metal stents for treating de novo common iliac artery disease with this technology. 103, 104 The internal iliac artery rarely requires treatment, but in select patients with bilateral severe internal iliac artery stenosis or occlusion and with hip claudication or even vasculogenic impotence, PTA with or without stenting may be reasonable. 105 
Common Femoral Artery
Historically, the CFA has been considered a stent-free zone because of repetitive hip flexion ( Figure 4B ). There have also been concerns about compromise of the pro- funda femoris artery, which, if it occurs, may result in conversion of stable patients from claudication to acute limb ischemia. The CFA is frequently heavily calcified and contains bulky and eccentric plaque that does not respond well to PTA alone. Surgical approaches with endarterectomy and vein patch angioplasty are safe with minor complications in moderate-to low-risk patients. 106 However, with advances in atherectomy and new stent designs such as the interwoven stents, the CFA may now be considered a potential target for endovascular intervention, especially among those with significant cardiovascular comorbidities and risk for inguinal infection. Recent retrospective data with >360 patients treated with PTA or stenting showed a 92.8% technical success rate and 1-year binary restenosis of 27.6%. 107 One small randomized trial showed better patency with surgery than with bioresorbable stenting for CFA; yet, the incidence of infection was higher for surgery. 108 Currently, we recommend surgical repair for most CFA disease because surgery can address the CFA, PFA, and the origin of the SFA. However, in high-risk patients, because of comorbidities for surgery, and in those who have undergone prior surgical incisions in the groin and are at risk for infection, endovascular intervention is reasonable.
Femoropopliteal Artery
The femoropopliteal segment is the longest artery in the body, and stents in this segment are associated with significant mechanical stressors including elongation, torsion, flexion, and extension. These forces have created challenges for endovascular strategies including stent fracture and lower patency rates. 25 However, despite the challenges, the SFA is the most common arterial segment affected by atherosclerosis in the leg, and there have been many attempts at identifying acceptable endovascular treatment options ( Figure 4C ). Therefore, treatment of femoropopliteal disease should be segmentalized according to lesion length, location, plaque morphology, and post-PTA results. In general, the distal SFA and popliteal artery can be treated with atherectomy plus DCB or with the interwoven stent given higher radial strength and lower likelihood of stent fracture (off-label). Proximal and mid SFA can be treated with DCB, DES, or even bare metal stents (Figure 4 ). For those with significant dissection and recoil post-DCB, most operators consider spot stenting with nitinol stents alone. At the present time, however, PTA alone to treat femoropopliteal lesions is not supported by current data and should rarely be performed as standalone treatment. [25] [26] [27] 
Tibiopedal Arteries
These arteries commonly require revascularization in patients with CLI. The lesions are typically long, calcified, and occlusive, and options are very limited. Despite this, a significant portion of patients with CLI do present with infragenicular disease. 24 The current treatment for these patients is mainly PTA; however, specialty balloons are also available without any prospective multicenter data showing superiority in comparison with PTA ( Figure  4D ). 54 A recent meta-analysis of PTA in the tibial arteries revealed a technical success rate of 91% with a 63% primary patency at 12 months and major amputation rate of only 15%. 109 The studies comprising the meta-analysis had many limitations including significant variability as to how patency was assessed and defined. 29, 109 Furthermore, many technical issues, such as proper balloon sizing, residual stenosis following PTA, and use of DES in proximal tibial arteries, were not considered. 29 Because many patients with CLI present with ischemic, nonhealing skin ulcerations, there has been an interest in the angiosome concept, involving a 3-dimensional assessment of the vascular territory between the skin and bone that is supplied by an artery and vein. 110 The concept of treating the angiosome-related artery is to revascularize the artery that is most likely going to restore adequate arterial circulation to heal the ulcer specifically. A recent meta-analysis showed that regardless of endovascular or bypass surgery, the angiosome approach was associated with significantly lower amputation-free survival. 111 However, this has been challenged by others because of the lack of randomized comparisons and recent small studies questioning its validity. 20, 112, 113 Balloon-expandable DES have also been studied in the proximal tibial arteries. The ACHILLES (Comparing Angioplasty and DES in the Treatment of Subjects With Ischemic Infrapopliteal Arterial Disease), DESTINY (Drug-Eluting Stents in the Critically Ischemic Lower Leg), and the YUKON-BTK (YUKON-Drug-Eluting Stent Below the Knee) trials evaluated DES versus bare metal stents for infrapopliteal arteries in individuals with claudication and CLI. [114] [115] [116] [117] Collectively, provisional stenting with DES is superior to bare metal stents or PTA with higher patency, reduced intervention, reduced amputation, and improved event-free survival. These coronary DESs are used off-label for the infrapopliteal arteries.
The IDEAS randomized controlled trial (Infrapopliteal Drug-Eluting Angioplasty Versus Stenting) compared a paclitaxel-coated balloon (DCB) (IN.PACT Amphirion, Medtronic) with DES in long (>70 mm) infrapopliteal lesions in patients with Rutherford class III to VI. 118 Fifty patients were randomly assigned to infrapopliteal DCB angioplasty (25 arteries in 25 limbs; DCB group) or primary DES placement (30 arteries in 27 limbs; DES group). At 6 months, the angiographic restenosis rate was significantly lower in DES (28% versus 57.9% in DCB; P=0.0457). There were no significant differences with regard to target lesion revascularization rates (7.7% in DES versus 13.6% in DCB; P=0. 65) .
DCBs have also been investigated for infrapopliteal disease with great enthusiasm. The DEBATE-BTK trial (Drug-Eluting Balloon in Peripheral Intervention for Below the Knee Angioplasty Evaluation) (demonstrated a significantly lower restenosis at 1 year with DCB in comparison with uncoated PTA (27% versus 74.3%, P<0.001, respectively). 119 However, the much larger randomized IN.PACT DEEP CLI trial failed to demonstrate this benefit. 120 In fact, the DCB arm resulted in higher amputation rates than PTA alone. Most recently, the BIOLUX P-II trial evaluated the Passeo-18 Lux DCB (Biotronik AG) in the tibial arteries, and this trial also failed to show improved primary patency at 6 months in comparison with PTA alone. 121 The negative results of the aforementioned studies have raised concerns regarding the role of DCB treatment below the knee. Unfortunately, both trials have had many limitations, and many unanswered questions remain. Importantly, although paclitaxel has performed well in the SFA, it remains to be seen if it is as effective as an antirestenotic agent in the tibial vessels. Furthermore, the atherosclerotic plaque in the tibial vessels may be pathologically different from those in the SFA, especially among those with diabetes mellitus. 122 Monckeberg medial calcification with absence of macrophages and lipid is commonly seen in tibial vessels of patients with diabetes mellitus and may imply different pathological mechanisms. 123 Understanding the different plaque morphology among those with diabetes mellitus and chronic kidney disease and between arterial territories may help our approach for a more successful endovascular treatment. Furthermore, proper balloon sizing, end points (time to wound healing), and postprocedure wound care are other important factors to consider when treating tibial arteries.
Drug-eluting self-expandable stents and drug-eluting bioresorbable scaffolds for infrapopliteal disease have also been studied in small trials and have shown encouraging results; however, at the present time, none of the above technologies are approved for infrapopliteal use in the United States. 124 
COMPLICATIOnS
All endovascular procedures have associated complications, and prompt recognition and management are critical for optimal patient outcomes. The most common complications are access site complications including bleeding and pseudoaneurysm, embolization, perforation, dissection, and infection. Device embolization or malfunction may also occur occasionally. The ultimate complication is death, which rarely occurs in the setting of endovascular percutaneous therapy for PAD.
Access Site Complications and Bleeding
The reported incidence of bleeding from peripheral procedures is variable and depends on a number of factors, including sheath size, access site location, activated partial thromboplastin time, 125 the presence of anticoagulants/potent antiplatelet agents, CFA disease, and patient weight. 126 Small access site bleeding events (ie, localized hematomas) are relatively common; however, when a retroperitoneal hemorrhage occurs, the risk to the patient is significant. The majority of retroperitoneal hemorrhages appear to occur in the first 3 hours following groin access. 127 A recent study of 27 048 patients undergoing peripheral intervention from the multicenter Vascular Quality Initiative showed a 3.5% vascular access site complication rates. Of these, the majority were minor (74.4%); however, 10.5% required surgical intervention and 9.7% required transfusion. 126 Ultrasound-guided access has been shown to reduce complications and risk of bleeding. 128 Alternative anticoagulants such as bivalirudin have also been suggested, but, given the associated cost, their role has been limited. 129 Pseudoaneurysm may occur occasionally; fortunately, the majority, if not all, can be treated with ultrasound-guided thrombin injection. 130 embolization Most operators believe that some degree of embolization occurs during all stages of percutaneous intervention for PAD; however, the majority of these appear to be clinically silent. The incidence has been reported to be between 1% and 20% in patients undergoing iliac and infrainguinal interventions. 131 Whether these emboli are truly benign or have small incremental clinical impact for the patient in the future is unknown. Risk factors for embolization are the presence of CTO, thrombus, atherectomy, and, occasionally, lipid-laden atheroma. 132 Because of this risk, preand postprocedure angiograms with full runoff to include the tibial and pedal arteries are generally recommended. When composition or acuity of the lesion is unknown, intra-arterial thrombolysis or use of an embolic protection device may be used. In general, atherectomy has a higher rate of embolization, and this can range from 0% to 2% depending on the studies published; however, most can be managed percutaneously if recognized promptly. 131 
Perforations
Perforations are rare but can occur anywhere within the vascular bed. They may occur as a result of wire manipulation, oversizing of balloons or stents, or as a result of inadvertent dilatation of collateral branches. Given the frequent subintimal crossing in the femoropopliteal and tibial vessels, the risk of perforation with aggressive atherectomy in this setting may be higher. Most perforations can be managed with prolonged balloon inflation. STATe OF The ART However, occasionally, a self-expanding covered stent is needed for the perforated iliac or femoropopliteal artery. For tibial arteries, an external blood pressure cuff inflated to 10 mm Hg above systolic blood pressure for 5 minutes and repeated as necessary may be sufficient. Rarely, anticoagulation must be reversed, but may be more frequently required when faced with large perforations involving the aorta or the iliac arteries.
Percutaneous Therapies for PAD
Dissections occur routinely after PTA and are generally benign. The majority can be treated with prolonged balloon inflation; however, stent deployment is occasionally required. The main challenge, as described above, is to objectively determine the hemodynamic significance of moderate to severe dissections.
Infections are rare with percutaneous interventions for PAD but can occur. Meticulous attention to hygiene and sterile field plus proper patient selection for closure devices should minimize such complications. In general, there are few data for pre-or postprocedure prophylactic antibiotic therapy.
AFFORDABLe heALTh CARe AnD The FUTURe OF enDOVASCULAR TheRAPY FOR PAD
The Affordable Health Care Act will have significant impact on the use of percutaneous endovascular therapies for PAD. Most recently, the Centers for Medicaid and Medicare Services convened a Medicare Evidence Development and Coverage Analysis Committee panel to examine strategies for the treatment of patients with PAD. The strategies evaluated included comprehensive medical therapy, a supervised exercise program for PAD, and revascularization. A coalition of 7 professional societies and organizations representing >150 000 allied health workers attended this meeting on behalf of their patients and have since published their responses to the questions posed to this panel. 133 A major goal of US healthcare reform is to reduce wasteful spending while improving quality, resulting in the so-called value-based health care. An important component of this is the bundled payments for care improvement initiative. Because of this, close attention is being paid to hospital readmission for PAD and for identifying tools that are cost-effective but yet provide the best long-term outcomes so that patients can be kept away from the hospital (Figure 1 ). 20 COnCLUSIOn Percutaneous endovascular intervention for PAD has evolved significantly since Charles Dotter performed the first endovascular procedure in a patient with CLI. 134 Many advances in devices, techniques, and approaches have been made in the past decade. It is important to note that long-term randomized data are now available with follow-up as long as 5 years for some devices. Multicenter registries such as the American College of Cardiology National Cardiovascular Data Repository Peripheral Vascular Interventions and the Society for Vascular Surgery Vascular Quality Initiative have been implemented, and we continue to learn from the wealth of information collected (Table 4 ). Important National Institutes of Health-sponsored trials such as the BEST CLI trial and commercial manufacturer-sponsored trials are ongoing or are planned. There is even unprecedented collaboration such as the Medicare Evidence Development and Coverage Analysis Committee coalition with multiple specialist groups working together on the behalf of patients with PAD. 133 However, despite all these advances and progress, we must remain vigilant and even more active in identifying the best and most costeffective treatment for each patient. Moving away from the anatomic approach to lower extremity PAD to a segmental approach that takes into account lesion location and length, stenosis versus occlusion, composition of plaque, and current device options may be 1 approach to personalized (segmentalized) treatment of PAD. This approach will also invariably include medical therapy, supervised exercise, and surgical options. The future will be bright for our field as long as we continue to innovate, collaborate, and evolve as physicians treating one of the most challenging and morbid of diseases, PAD. 
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